Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Biologic therapy.

Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:4City/State/Province:Aichi
Treatments:Biologic therapyHospital:Nagoya City University Graduate School of Medical Sciences
Drugs:Journal:Link
Date:Mar 2012

Description:

Patients:
This study involved 27 patients with relapsed, aggressive CCR4-positive adult T-cell leukemia-lymphoma. The median age was 64 years and 44% of the patients were male.

Treatment:
Patients were treated with the biologic therapy agent KW-0761, an anti-CCR4 monoclonal antibody, which targets cancer cells to be destroyed by the immune system.

Toxicities:
The most severe toxicities were of grade 4 and included lymphopenia and thrombocytopenia. Grade 3 rash and neutropenia were also reported.

Results:
The reported median overall survival was 13.7 months.

Support:
This study was supported by the pharmaceutical company Kyowa Hakko Kirin.

Correspondence: Dr. Takashi Ishida; email: [email protected]



Back